

# **Frequently Asked Questions: Amendments to Policy for Pharmacy Payments under the Long-Term Care Home Capitation Funding Model, 2020**

This Questions and Answers document accompanies the Executive Officer (EO) Notice: Amendments to Policy for Pharmacy Payments under the Long-Term Care Home Capitation Funding Model, 2020 (the “Policy”)

## **1. What change is being made effective April 1, 2021?**

Effective April 1, 2021, The Ministry is amending the Policy to change the annual fees-per-bed / the fee reduction schedule under the fee-per-bed capitation model.

Previously, the Policy provided that primary pharmacy service provider would be paid an annual fee-per-bed (in monthly allotments) as follows:

- \$1500 in Fiscal Year (FY) 2019/20 (i.e., \$125 per month; total \$375 for the remainder of 2019/20)
- \$1,500 in FY 2020/21 (\$125/month)
- \$1,400 in FY 2021/22 (\$116.67/month)
- \$1,300 in FY 2022/23 (\$108.33/month)
- \$1,200 in FY 2023/24 (\$100/month)

Effective April 1, 2021, the Ministry is revising the annual fees-per-bed for FY 2021/22 to FY 2024/25. Primary pharmacy service providers will be paid an annual fee-per-bed (in monthly allotments), in accordance with the Policy, over the next four FYs as follows:

- \$1,500 in FY 2021-2022 (\$125/month)
- \$1,400 in FY 2022-2023 (\$116.67/month)
- \$1,300 in FY 2023-2024 (\$108.33/month)
- \$1,200 in FY 2024-2025 (\$100/month)

**2. How much will primary pharmacy service providers to LTC homes be paid under the capitation model for FY 2021/22 and future FY?**

Effective April 1, 2021, the Ministry revised annual fees-per-bed for FY 2021/22 to FY 2024/25. Primary pharmacy service providers will be paid an annual fee-per-bed (in monthly allotments), in accordance with the Policy, over the next four FYs as follows:

- \$1,500 in FY2021-2022 (\$125/month)
- \$1,400 in FY2022-2023 (\$116.67/month)
- \$1,300 in FY2023-2024 (\$108.33/month)
- \$1,200 in FY2024-2025 (\$100/month)

**3. What remains the same?**

All other aspects of the Policy remain the same. Please refer to the December 16, 2019 Executive Officer Notice and accompanying documents and the Ontario Drug Programs Reference Manual for additional information.